Cargando…
Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
BACKGROUND: Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. METHODS: A total of 78 patients d...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202309/ https://www.ncbi.nlm.nih.gov/pubmed/34178124 http://dx.doi.org/10.1177/1759720X211014020 |
_version_ | 1783707955190824960 |
---|---|
author | Varenna, Massimo Braga, Vania Gatti, Davide Iolascon, Giovanni Frediani, Bruno Zucchi, Francesca Crotti, Chiara Nannipieri, Fabrizio Rossini, Maurizio |
author_facet | Varenna, Massimo Braga, Vania Gatti, Davide Iolascon, Giovanni Frediani, Bruno Zucchi, Francesca Crotti, Chiara Nannipieri, Fabrizio Rossini, Maurizio |
author_sort | Varenna, Massimo |
collection | PubMed |
description | BACKGROUND: Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. METHODS: A total of 78 patients diagnosed with CRPS-1 (aged 59.5 ± 10.3, 66.7% female) were randomly assigned to 25 mg (i.m.) neridronate (N = 41) given once daily for 16 consecutive days or placebo control (N = 37). Efficacy was assessed after 30 days using a visual analogue scale (VAS) pain score and the number of patients achieving ⩾50% reduction in VAS score. Change in clinical signs and symptoms, quality of life (QoL) using Short Form Health Survey (SF-36) and the McGill Pain Questionnaire were also assessed. RESULTS: After 30 days, VAS score decreased significantly to a greater extent in neridronate-treated patients versus placebo (31.9 ± 23.3 mm versus 52.3 ± 27.8 mm, p = 0.0003). Furthermore, the proportion of patients achieving a VAS reduction of ⩾50% was greater in the neridronate group (65.9% versus 29.7%, p = 0.0017). Clinical signs and symptoms were improved significantly in the neridronate group versus placebo for edema (72.5% versus 79.9%, p = 0.03), pain during motion (70% versus 83.3%, p = 0.0009), allodynia (20% versus 63.3%, p = 0.0004), and hyperalgesia (20% versus 56.7%, p = 0.0023). Whereas no difference was observed for QoL measures using the SF-36 questionnaire, three of the four pain variables using the McGill Pain Questionnaire improved significantly in the neridronate group. No serious drug-related adverse events were reported during the study. CONCLUSION: In patients with acute CRPS-1, i.m. injections of 25 mg neridronate were associated with clinically relevant benefit compared with placebo controls. TRIAL REGISTRATION: EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-28 |
format | Online Article Text |
id | pubmed-8202309 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82023092021-06-24 Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study Varenna, Massimo Braga, Vania Gatti, Davide Iolascon, Giovanni Frediani, Bruno Zucchi, Francesca Crotti, Chiara Nannipieri, Fabrizio Rossini, Maurizio Ther Adv Musculoskelet Dis Original Research BACKGROUND: Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. METHODS: A total of 78 patients diagnosed with CRPS-1 (aged 59.5 ± 10.3, 66.7% female) were randomly assigned to 25 mg (i.m.) neridronate (N = 41) given once daily for 16 consecutive days or placebo control (N = 37). Efficacy was assessed after 30 days using a visual analogue scale (VAS) pain score and the number of patients achieving ⩾50% reduction in VAS score. Change in clinical signs and symptoms, quality of life (QoL) using Short Form Health Survey (SF-36) and the McGill Pain Questionnaire were also assessed. RESULTS: After 30 days, VAS score decreased significantly to a greater extent in neridronate-treated patients versus placebo (31.9 ± 23.3 mm versus 52.3 ± 27.8 mm, p = 0.0003). Furthermore, the proportion of patients achieving a VAS reduction of ⩾50% was greater in the neridronate group (65.9% versus 29.7%, p = 0.0017). Clinical signs and symptoms were improved significantly in the neridronate group versus placebo for edema (72.5% versus 79.9%, p = 0.03), pain during motion (70% versus 83.3%, p = 0.0009), allodynia (20% versus 63.3%, p = 0.0004), and hyperalgesia (20% versus 56.7%, p = 0.0023). Whereas no difference was observed for QoL measures using the SF-36 questionnaire, three of the four pain variables using the McGill Pain Questionnaire improved significantly in the neridronate group. No serious drug-related adverse events were reported during the study. CONCLUSION: In patients with acute CRPS-1, i.m. injections of 25 mg neridronate were associated with clinically relevant benefit compared with placebo controls. TRIAL REGISTRATION: EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-28 SAGE Publications 2021-06-11 /pmc/articles/PMC8202309/ /pubmed/34178124 http://dx.doi.org/10.1177/1759720X211014020 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Varenna, Massimo Braga, Vania Gatti, Davide Iolascon, Giovanni Frediani, Bruno Zucchi, Francesca Crotti, Chiara Nannipieri, Fabrizio Rossini, Maurizio Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study |
title | Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study |
title_full | Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study |
title_fullStr | Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study |
title_full_unstemmed | Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study |
title_short | Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study |
title_sort | intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202309/ https://www.ncbi.nlm.nih.gov/pubmed/34178124 http://dx.doi.org/10.1177/1759720X211014020 |
work_keys_str_mv | AT varennamassimo intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT bragavania intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT gattidavide intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT iolascongiovanni intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT fredianibruno intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT zucchifrancesca intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT crottichiara intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT nannipierifabrizio intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy AT rossinimaurizio intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy |